DiaGenic ASA (NEL)-医療機器分野:企業M&A・提携分析

◆英語タイトル:DiaGenic ASA (NEL) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8010919
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月21日
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ノルウェー
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
DiaGenic ASA (DiaGenic) is a medical device company that develops innovative in vitro diagnostic products for early detection of diseases. The company specializes in developing blood-based biomarkers. Its ADtect product is a blood test that helps distinguish mild to moderate range AD from the absence of dementia. DiaGenic also has IP position, unique access to biobanks and mature technology in late stage development of products for commercialization in major markets. The company’s tests are based on the observation that a focal lesion or disorder gives rise to a systemic response which can be measured in the blood. DiaGenic is headquartered in Oslo, Norway.

DiaGenic ASA (NEL) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
DiaGenic ASA, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
DiaGenic ASA, Medical Equipment Deals By Type, 2011 to YTD 2017 6
DiaGenic ASA, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
DiaGenic ASA, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
DiaGenic ASA, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
DiaGenic ASA, Medical Equipment, Deal Details 10
Partnerships 10
DiaGenic Enters Into Co-Development Agreement With GE Healthcare 10
Equity Offering 11
DiaGenic Raises USD5.4 Million in Private Placement of Shares 11
DiaGenic Raises USD8 Million in Rights Offering Of Shares 12
DiaGenic Completes Rights Offering Of Shares For US$0.5 Million 13
DiaGenic Completes Private Placement Of Shares For US$5.2 Million 14
Asset Transactions 15
DiaGenic Plans To Sell Its Assets 15
DiaGenic ASA – Key Competitors 16
DiaGenic ASA – Key Employees 17
DiaGenic ASA – Locations And Subsidiaries 18
Head Office 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
DiaGenic ASA, Medical Equipment, Key Facts, 2016 2
DiaGenic ASA, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
DiaGenic ASA, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
DiaGenic ASA, Medical Equipment Deals By Type, 2011 to YTD 2017 6
DiaGenic ASA, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
DiaGenic ASA, Deals By Market, 2011 to YTD 2017 8
DiaGenic ASA, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
DiaGenic Enters Into Co-Development Agreement With GE Healthcare 10
DiaGenic Raises USD5.4 Million in Private Placement of Shares 11
DiaGenic Raises USD8 Million in Rights Offering Of Shares 12
DiaGenic Completes Rights Offering Of Shares For US$0.5 Million 13
DiaGenic Completes Private Placement Of Shares For US$5.2 Million 14
DiaGenic Plans To Sell Its Assets 15
DiaGenic ASA, Key Competitors 16
DiaGenic ASA, Key Employees 17

★海外企業調査レポート[DiaGenic ASA (NEL)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • NewYork-Presbyterian Hospital:企業の戦略的SWOT分析
    NewYork-Presbyterian Hospital - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Safe Orthopaedics SA (SAFOR):企業の製品パイプライン分析2018
    Summary Safe Orthopaedics SA (Safe Orthopaedics) is medical device company that manufactures and markets devices for spinal surgery. The company’s products comprise implants and surgical instruments. It offers modular cervical cages, percutaneous auto-correction screws, modular anchorage screws, per …
  • Love’s Travel Stops & Country Stores Inc:企業の戦略・SWOT・財務情報
    Love’s Travel Stops & Country Stores Inc - Strategy, SWOT and Corporate Finance Report Summary Love’s Travel Stops & Country Stores Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Nidec Corporation:企業の戦略・SWOT・財務情報
    Nidec Corporation - Strategy, SWOT and Corporate Finance Report Summary Nidec Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Investor AB (INVE B):企業の財務・戦略的SWOT分析
    Investor AB (INVE B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • TE Connectivity Ltd (TEL):電力:M&Aディール及び事業提携情報
    Summary TE Connectivity Ltd (TE Connectivity), formerly Tyco Electronics Ltd, is a technology company. It designs and manufactures connectivity and sensor solutions. The company offers connectors; sensors; relays; heat shrink tubing; wire and cable; antennas and circuit protection devices. Its solut …
  • Mereo Biopharma Group Plc (MPH):製薬・医療:M&Aディール及び事業提携情報
    Summary Mereo Biopharma Group Plc (Mereo), formerly Mereo Biopharma Group Ltd is a specialty bio-pharmaceutical company which develops novel medicines for the treatment of rare and specialty diseases. The company’s pipeline products include BPS-804, which is used for the treatment of brittle bone sy …
  • Eyevensys SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Eyevensys SAS (Eyevensys) is a clinical stage biotechnology company developing non-viral gene therapies for ophthalmic diseases. Its lead product, EYS-606, is a soluble TNFa receptor plasmid associated with the ETIS device to treat non-infectious intermediate and posterior uveitis(NIU); EYS- …
  • FibroGen Inc (FGEN)-製薬・医療分野:企業M&A・提携分析
    Summary FibroGen Inc (FibroGen) is a biotechnology company that discovers, develops and commercializes new therapeutics. The company’s pipeline product portfolio includes FG-4592, an oral small molecule inhibitor of HIF prolyl hydroxylases that is used for the treatment of anemia in chronic kidney d …
  • Seven-Eleven Japan Co., Ltd.:企業の戦略・SWOT・財務情報
    Seven-Eleven Japan Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Seven-Eleven Japan Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Geistlich Pharma AG:企業の戦略的SWOT分析
    Geistlich Pharma AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Energy Resources of Australia Ltd. (ERA):企業の財務・戦略的SWOT分析
    Energy Resources of Australia Ltd. (ERA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • SONIFI Solutions, Inc:企業の戦略的SWOT分析
    SONIFI Solutions, Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Kongsberg Maritime AS:企業の戦略的SWOT分析
    Kongsberg Maritime AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Immupharma Plc (IMM):企業の財務・戦略的SWOT分析
    Immupharma Plc (IMM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Northwestern University:企業のM&A・事業提携・投資動向
    Northwestern University - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Northwestern University Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Pebblebrook Hotel Trust:企業のM&A・事業提携・投資動向
    Pebblebrook Hotel Trust - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Pebblebrook Hotel Trust Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Hengyuan Refining Company Bhd (HENGYUAN):企業の財務・戦略的SWOT分析
    Hengyuan Refining Company Bhd (HENGYUAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Pebblebrook Hotel Trust:企業の戦略・SWOT・財務情報
    Pebblebrook Hotel Trust - Strategy, SWOT and Corporate Finance Report Summary Pebblebrook Hotel Trust - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Cytox Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Cytox Ltd (Cytox) is a diagnostic and prognostic service provider that develops services for neurodegenerative disorders. The company’s blood tests are used to predict, which patients with MCI will develop Alzheimer's disease. Its biomarkers are based on the cell cycle hypothesis of Alzheime …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆